Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7A is a human challenge strain of Enterotoxigenic *Escherichia coli* (ETEC) used in controlled human infection model (CHIM) studies to evaluate the safety and protective efficacy of candidate vaccines and therapeutics. It is a live bacterial inoculum, serotyped as O148:H28, that expresses the colonization factor CS6 along with both heat-labile (LT) and heat-stable (ST) enterotoxins. Originally isolated from a US military adult who developed acute diarrhea in Vietnam, B7A is currently the only CS6-expressing ETEC challenge strain utilized in human clinical trials. In studies such as those conducted by the Johns Hopkins Bloomberg School of Public Health, the strain is orally administered to healthy adult volunteers to induce moderate-to-severe diarrhea, serving as a standardized biological model for testing interventions like Anti-CS6 Bovine Serum Immunoglobulin (BSIgG).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B7A-CS6-expressing ETEC.